OGXI Key Stats
| Income Statement | |
| Revenue TTM | 23.86M |
| Revenue Quarterly YoY Growth | 285.7% |
| EPS Diluted TTM | -1.430 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -20.94M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | -131.9% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 153.15M |
| Enterprise Value | 89.45M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 2.541 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | -10.80M |
| Return on Equity | -29.99% |
OGXI News
- Nasdaq stocks posting largest percentage increases May 13
- ONCOGENEX PHARMACEUTICALS, INC. Financials May 10
- OncoGenex Loss Lower than Expected May 6
- OncoGenex Loss Lower than Expected - Analyst Blog Zacks May 6
- OncoGenex Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcr... May 3
- OncoGenex Pharmaceuticals Provides Clinical Development Program Overview and Rep... May 2
- OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview a... May 2
- ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Fi... May 2
- Q1 2013 Oncogenex Pharmaceuticals, Inc. Earnings Release - After Market Close May 2
- OncoGenex Pharmaceuticals Becomes Oversold (OGXI) May 1
OGXI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). OncoGenex Pharmaceuticals is down 17.99% over the last year vs S&P 500 Total Return up 31.59%, Acorda Therapeutics up 48.48%, and Merus Labs International down 65.00%.
OGXI Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these OGXI related companies
Pro Ratings for OGXI
Pro Report PDF for OGXI
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download OGXI Pro Report PDF
Pro Strategies Featuring OGXI
Did OncoGenex Pharmaceuticals make it into our Pro Portfolio Strategies?
OGXI Profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Other OGXI Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OGXI | 10.44 | -0.06 | -0.57% | 153.15M |
